Issues for countries considering introducing the “fourth hurdle”: The case of Hungary
- 1 August 2004
- journal article
- general essays
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 20 (3) , 337-341
Abstract
Objectives:This study outlines the needs and current development of the “fourth hurdle” (i.e., requirement of effectiveness and cost-effectiveness data for drug coverage policy decisions) in Hungary, describes the legal background and seeks to address some of the most important questions in this field.Methods:The study draws on international experiences and discusses five issues that a given jurisdiction needs to consider before introducing the “fourth hurdle” for pharmaceuticals.Results:The “fourth hurdle” is very relevant in Hungary because many existing drugs are unevaluated and many new, expensive drugs are becoming available. On the other hand, the existing resources for health technology assessment, including economic evaluation, are quite limited. All the five issues are relevant in the Hungarian setting and were helpful in determining exactly how the “fourth hurdle” should be applied.Conclusions:The most important issue seems to be that the implementation of the “fourth hurdle” needs to be achieved in a way consistent with the limited resources for HTA in Hungary. Specifically this means that, in setting priorities for drugs to evaluate, additional criteria need to be applied. In particular, priority should be given to assessing drugs that have been evaluated in other countries, because this affords the opportunity to adapt existing studies or models to the Hungarian situation.Keywords
This publication has 10 references indexed in Scilit:
- Will there ever be a European drug pricing and reimbursement agency?The European Journal of Health Economics, 2003
- Priority setting for health technology assessment in The Netherlands: principles and practiceHealth Policy, 2002
- Pricing and reimbursement of drugs and medical devices in HungaryThe European Journal of Health Economics, 2002
- Time for a change in drug licensing requirements?The European Journal of Health Economics, 2002
- Setting priorities for the adoption of health technologies on a national level — the Israeli experienceHealth Policy, 2000
- Problems With the Interpretation of Pharmacoeconomic AnalysesJAMA, 2000
- Pharmacoeconomic Evaluation in the Real WorldPharmacoEconomics, 1999
- Health policy issues and applications for evidence-based medicine and clinical practice guidelinesHealth Policy, 1998
- Basing Prescription Drug Payment on Economic Analysis: The Case of AustraliaHealth Affairs, 1992
- Economic Analysis as an Aid to Subsidisation DecisionsPharmacoEconomics, 1992